top of page
BioLattice Ophthalmics is developing CorneaClear™, a first-in-class engineered corneal implant for full-thickness cornea replacement. It addresses the global donor shortage and aims to become a new standard of care. CorneaClear™ is compatible with existing surgical procedures and eliminates the immunologic risks associated with donor tissue.

Lead Program & Pipeline

  • Lead product: CorneaClear™ – a bioengineered, full-thickness corneal implant

  • Designed as a scalable, ambient-stable alternative to donor cornea tissue

  • Targets global corneal blindness affecting over 13 million people

  • Enables standard penetrating keratoplasty with no new surgical training required

  • Aims to become the new standard of care for corneal replacement

Technology Differentiators

  • Implanted using standard penetrating keratoplasty techniques — no retraining required

  • Stable at ambient temperature, enabling broad accessibility

  • Eliminates immune rejection risks and donor tissue variability

  • Scalable, GMP-compatible manufacturing process for consistent quality and supply

Stage & Investment

  • Stage: Preclinical

  • Funding Raised: $1.25M oversubscribed pre-seed round (Dec 2024)

  • IP: Provisional patent filed; non-provisional planned for 2025

  • Collaborators: Wills Eye Hospital, Thomas Jefferson University, Lehigh University

What's Next

  • Complete pilot animal studies and FDA pre-submission meeting

  • Initiate GLP studies and prepare 510(k) regulatory strategy

  • Build reimbursement and surgeon education packages

  • Open $2M seed round to support FDA IDE submission and clinical development

Leadership

Amelia-Zellander.jpg
Amelia Zellander, PhD
Founder & CEO
1721935130524.jpg
Linda Alunkal, MBA
Co-founder & COO
bottom of page